



PERSONAL INFORMATION

Name MAURIZIO MARTINI

Address Via Palombara, 3, 01033, Civita Castellana (VT)

Work address Dipartimento di Patologia umana dell'adulto e dell'età evolutiva "Gaetano Barresi" Via Consolare Valeria 1, Azienda Ospedaliera Universitaria Policlinico "G. Martino", 98125, Gazzi, Messina

Telephone 090/2212545

E-mail maurizio.martini@unime.it ; maurizio.martini@polime.it;

Nationality Italiana

Birth date 04/03/1971; CF. MRTMRZ71C04H501Q

EDUCATION

1997: M.D. Medicine Doctor with honor, Faculty of Medicine, Catholic University of Sacred Heart, Rome

2002: Specialist in Pathology with honor, Faculty of Medicine, Catholic University of Sacred Heart, Rome

2007: Ph.D. Research Doctorate in "Hemopathology", Catholic University of Sacred Heart, Rome

From 2007 to 2011: Post-doct, Molecular Pathology laboratory, Research project: Molecular characterization of chronic myeloproliferative diseases. Supervisor: Prof. Larocca Luigi Maria

2011: Assistant Professor in Pathology, (Anatomia Patologica, Scientific Sector MED/08)

2012: Scientific Director of the Molecular Pathology Laboratory, Catholic University of Sacred Heart, Rome (Servizio di Istopatologia e Citodiagnosi, Ospedale Agostino Gemelli, Roma)

2014: National Scientific Qualification for Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2014: Assistant Medical Director, (Servizio di Istopatologia e Citodiagnosi, Ospedale Agostino Gemelli, Roma)

2016: Director of the Molecular pathology laboratories.

2018: National Scientific Qualification for Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2020: National Scientific Qualification for Full Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2022: Associate Professor in Pathology, University of Messina, Messina

2022: Assistant Medical Director, (Servizio di Istopatologia e Citodiagnosi, Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina)

POSITION HELD Assistant Professor in Pathology, Assistant Medical Director in Pathology, Scientific Director of Molecular Pathology Laboratory

MOTHER TONGUE ITALIAN

OTHER LANGUAGES ENGLISH (READING SKILL: VERY GOOD; WRITING SKILL: VERY GOOD; VERBAL SKILL: GOOD)

HONOURS

From 2001 to 2002: Annual grant for young researcher, Faculty of Medicine, Catholic University of Sacred Heart

2003: Annual grant by Italian Association for Cancer Research (AIRC). Research project: Molecular characterization of chronic myeloproliferative diseases.

From 2005 to 2010: Annual grant by Faculty of Medical Biotechnology, Catholic University of Sacred Heart. Research project: Biotechnological applications in Pathology. Supervisor: Prof. Larocca Luigi Maria.

From 2011 to 2012: Annual grant by Faculty of Medicine, Catholic University of Sacred Heart. Linea D1.

2014-18: National Scientific Qualification for Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

2021: Assistant Professor in Pathology (Anatomia Patologica: seconda fascia, MED/08)

RESEARCH INTERESTS

Hematopathology: Normal and pathological hematopoiesis; chronic myeloproliferative diseases; acute promyelocytic leukaemia; lymphomagenesis in immunocompetent and immunocompromised (HIV) patients; infection (EBV-HIV) and lymphomagenesis; chronic lymphocytic leukemia, Richter syndrome; Hodgkin disease; non-Hodgkin lymphoma; large B cell lymphoma; Primary cerebral lymphomatoid granulomatosis; Primary central nervous system lymphoma; healthy and pathological hematopoietic niche; circulating hematopoietic and endothelial precursors; hematopoietic cancer stem cell; apoptosis and hematopoiesis.

Glial and central nervous system cancer: Glioblastoma pathogenesis; Glioblastoma cancer stem cell; Angiogenesis in Glioblastoma, Cancer stem cell transdifferentiation, Targeted therapy in Glioblastoma; autophagic programmed cell death and glioblastoma; genome characterization of glioblastoma subtypes; recurrent glioblastoma; chordoma; anaplastic ependymoma.

Gastrointestinal tumor: colorectal cancer pathogenesis; targeted therapy in colorectal cancer; inflammatory bowel disease and cancer; gastrointestinal stromal tumor; hereditary gastrointestinal tumor syndrome; gastrointestinal cancer stem cell; neoangiogenesis in colorectal cancer; secondary resistance in colorectal cancer targeted therapy.

Lung cancer: targeted therapy and non-small cell lung carcinoma; neuroendocrine cancer.

Thyroid cancer: papillary cancer; follicular lesion of thyroid; medullary thyroid cancer.

Genitourinary cancer: endometrial carcinoma and endometriosis; prostate cancer and inflammation; seminoma and germinal cell tumor.

UNIVERSITY TEACHING COURSES

Dr. Martini teaches in several university courses in the Medical and Dentistry Faculties, Catholic University of Sacred Heart, Faculty of Medical Biotechnology, Catholic University of Sacred Heart, Pathology postgraduate school, Hematology and Urology postgraduate school, Doctoral school of Oncology, University masters (first and second level).

REVIEWER ACTIVITY

Scientific Journal: Journal of Clinical Oncology, Blood, New England Journal of Medicine, Journal of Experimental & Clinical Cancer Research, Haematologica, Neoplasia, International Journal of Cancer, Oncotarget, Oncogene, Modern Pathology, American Journal of Surgical Pathology, Mediterranean Journal of Hematology and infectious Diseases, Pediatric Blood & Cancer, International Journal of Molecular Sciences.

Member of the editorial Board: BMC Cancer, IJMM, Cancers, Diagnostics, MJHID.

National and International Funding and Grant Associations: Italian Miur and Firc; Anvur Cineca; Cancer Research UK, Arc France, Fondazione delle Scienze della Repubblica Ceca.

BIBLIOMETRIC INDEXES

Dr. Martini is the author of 275 scientific publications cited by PubMed.org:

- a) first name in 25
- b) second name in 35
- c) seniorship in 15,

Dr. Martini has a total IMPACT FACTOR greater than 800 e as first name greater than 150 (average as first name, IF 6,7).

1) SciVerse Scopus 15/03/2024

H. index 45

Documents selected: 275

Total citations: 6655

Academic age: 230.0 year/s

2) ISI Web of Knowledge, Web of Science 15/03/2024

Results found: 358

Sum of the Times Cited: 6050

Sum of Times Cited by Patents: 28

h-index: 43

3) Scholar 15/03/2024

H index: 53

Citations: 10671

I10 index: 251

4) Dr. Martini has become part of the best Italian scientists from June 2015, with an H-index of 53 in VIA Academy, <http://www.topitalianscientists.org>

LIST OF PUBLICATIONS IN FULL:

1. Pizzimenti C, Fiorentino V, Germanò A, Martini M, Ieni A, Tuccari G. Pilocytic astrocytoma: The paradigmatic entity in low-grade gliomas (Review). *Oncol Lett.* 2024 Feb 8;27(4):146.
2. Pecci V, Troisi F, Aiello A, De Martino S, Carlino A, Fiorentino V, Ripoli C, Rotili D, Pierconti F, Martini M, Porru M, Pinto F, Mai A, Bassi PF, Grassi C, Gaetano C, Pontecorvi A, Strigari L, Farsetti A, Nanni S. Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer. *Cancer Cell Int.* 2024 Feb 5;24(1):56.
3. Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, Criscitiello C, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. *Hum Pathol.* 2024 Feb;144:22-27.
4. Adle-Biassette H, Ricci R, Martin A, Martini M, Ravegnini G, Kaci R, Gélébart P, Poirot B, Sándor Z, Lehman-Che J, Tóth E, Papp B. Sarco/endoplasmic reticulum calcium ATPase 3 (SERCA3) expression in gastrointestinal stromal tumours. *Pathology.* 2024 Apr;56(3):343-356.
5. Di Gianfrancesco L, Crestani A, Amodeo A, Corsi P, De Marchi D, Miglioranza E, Lista G, Simonetti F, Busetto GM, Maggi M, Pierconti F, Martini M, Montagner IM, Tormen D, Scapinello A, Marino F, Porreca A. The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review. *Diagnostics (Basel).* 2023 Oct 3;13(19):3119.
6. Franchina M, Pizzimenti C, Fiorentino V, Martini M, Ricciardi GRR, Silvestris N, Ieni A, Tuccari G. Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes. *Int J Mol Sci.* 2023 Aug 14;24(16):12795.
7. Fiorentino V, Pizzimenti C, Pierconti F, Lentini M, Ieni A, Caffo M, Angileri F, Tuccari G, Fadda G, Martini M, Larocca LM. Unusual localization and clinical presentation of primary central nervous system extranodal marginal zone B-cell lymphoma: A case report. *Oncol Lett.* 2023 Aug 4;26(3):408.

8. Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey. *Crit Rev Oncol Hematol*. 2023 Oct;190:104103.
9. Fiorentino V, Pizzimenti C, Franchina M, Rossi ED, Tralongo P, Carlino A, Larocca LM, Martini M, Fadda G, Pierconti F. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples. *Int J Mol Sci*. 2023 Aug 6;24(15):12489.
10. Fiorentino V, Tralongo P, Larocca LM, Pizzimenti C, Martini M, Pierconti F. First-line ICIs in renal cell carcinoma. *Hum Vaccin Immunother*. 2023 Aug 1;19(2):2225386.
11. Pizzimenti C, Fiorentino V, Ieni A, Rossi ED, Germanà E, Giovannella L, Lentini M, Alessi Y, Tuccari G, Campennì A, Martini M, Fadda G. BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category. *Int J Mol Sci*. 2023 Jun 12;24(12):10024.
12. Pizzimenti C, Fiorentino V, Franchina M, Martini M, Giuffrè G, Lentini M, Silvestris N, Di Pietro M, Fadda G, Tuccari G, Ieni A. Autophagic-Related Proteins in Brain Gliomas: Role, Mechanisms, and Targeting Agents. *Cancers (Basel)*. 2023 May 5;15(9):2622.
13. Gatsiou A, Tual-Chalot S, Napoli M, Ortega-Gomez A, Regen T, Badolia R, Cesarini V, Garcia-Gonzalez C, Chevre R, Ciliberti G, Silvestre-Roig C, Martini M, Hoffmann J, Hamouche R, Visker JR, Diakos N, Wietelmann A, Silvestris DA, Georgiopoulos G, Moshfegh A, Schneider A, Chen W, Guenther S, Backs J, Kwak S, Selzman CH, Stamatelopoulos K, Rose-John S, Trautwein C, Spyridopoulos I, Braun T, Waisman A, Gallo A, Drakos SG, Dimmeler S, Sperandio M, Soehnlein O, Stellos K. The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation. *Immunity*. 2023 May 9;56(5):979-997.e11.
14. D'Alessandris QG, Battistelli M, Pennisi G, Offi M, Martini M, Cenci T, Falchetti ML, Lauretti L, Olivi A, Pallini R, Montano N. Telomerase inhibition in malignant gliomas: a systematic review. *Expert Rev Mol Med*. 2023 Mar 15;25:e10.
15. Girolami I, Marletta S, Fiorentino V, Battocchio S, Cerbelli B, Fiamengo B, Gerosa C, Gianatti A, Morelli L, Riva G, Zagami MG, Fusco N, Munari E, L'Imperio V, Pagni F, Morbini P, Martini M, Eccher A. Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma. *J Pers Med*. 2023 Feb 18;13(2):363.
16. Di Bonaventura R, Lauretti L, Martini M, Cenci T, Di Monaco G, Palombi D, Ceccarelli GM, Chiesa S, Gessi M, Granitto A, Albanese A, Larocca LM, D'Alessandris QG, Pallini R, Olivi A. Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study. *J Pers Med*. 2023 Jan 25;13(2):206.
17. Turco LC, Pedone Anchora L, Fedele C, Inzani F, Piermattei A, Martini M, Volpe M, Marchetti S, Santangelo R, Bizzarri N, Cosentino F, Vargiu V, De Ninno M, Macchia G, Valentini V, Zannoni G, Scambia G, Ferrandina G. Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery. *Int J Gynecol Cancer*. 2023 Apr 3;33(4):489-497.

18. Giacò L, Palluzzi F, Guido D, Nero C, Giacomini F, Duranti S, Bria E, Tortora G, Cenci T, Martini M, De Paolis E, Onori ME, De Bonis M, Normanno N, Scambia G, Minucci A. A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants. *Cancers (Basel)*. 2022 Dec 13;14(24):6152.
19. Sapuppo E, Brunetti O, Tessitore D, Brandi G, Di Giovanni N, Fadda G, Luchini C, Martini M, Quaresmini D, Russo A, Santarpia M, Scarpa A, Scartozzi M, Tuccari G, Franchina T, Silvestris N. Rare histotypes of epithelial biliary tract tumors: A literature review. *Crit Rev Oncol Hematol*. 2023 Jan;181:103892.
20. Ficarra V, Rossanese M, Gilante M, Foti M, Macchione L, Mucciardi G, Martini M, Giannarini G. Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study. *Prostate Cancer Prostatic Dis*. 2023 Sep;26(3):568-574.
21. Piro G, Carbone C, Agostini A, Esposito A, De Pizzol M, Novelli R, Allegretti M, Aramini A, Caggiano A, Granitto A, De Sanctis F, Ugel S, Corbo V, Martini M, Lawlor RT, Scarpa A, Tortora G. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. *Br J Cancer*. 2023 Jan;128(2):331-341.
22. Pierconti F, Rossi ED, Cenci T, Carlino A, Fiorentino V, Totaro A, Sacco E, Palermo G, Iacovelli R, Larocca LM, Bassi PF, Martini M. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group. *Cancer Cytopathol*. 2023 Mar;131(3):158-164.
23. Di Bonaventura R, Martini M, Cenci T, Caccavella VM, Barresi V, Gessi M, Albanese A, Lauretti L, Pallini R, D'Alessandris QG, Olivi A. Dissecting Stemness in Aggressive Intracranial Meningiomas: Prognostic Role of SOX2 Expression. *Int J Mol Sci*. 2022 Oct 2;23(19):11690.
24. Chiesa S, Mangraviti A, Martini M, Cenci T, Mazzarella C, Gaudino S, Bracci S, Martino A, Della Pepa GM, Offi M, Gessi M, Russo R, Martucci M, Beghella Bartoli F, Larocca LM, Lauretti L, Olivi A, Pallini R, Balducci M, D'Alessandris QG. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma. *Sci Rep*. 2022 Sep 28;12(1):16265.
25. Fiorentino V, Straccia P, Tralongo P, Musarra T, Pierconti F, Martini M, Fadda G, Rossi ED, Larocca LM. DOG1 as an Immunohistochemical Marker of Acinic Cell Carcinoma: A Systematic Review and Meta-Analysis. *Int J Mol Sci*. 2022 Aug 26;23(17):9711.
26. Cesarini V, Silvestris DA, Galeano F, Tassinari V, Martini M, Locatelli F, Gallo A. ADAR2 Protein Is Associated with Overall Survival in GBM Patients and Its Decrease Triggers the Anchorage-Independent Cell Growth Signature. *Biomolecules*. 2022 Aug 19;12(8):1142.
27. Pedini G, Buccarelli M, Bianchi F, Pacini L, Cencelli G, D'Alessandris QG, Martini M, Giannetti S, Sasso F, Melocchi V, Farace MG, Achsel T, Larocca LM, Ricci-Vitiani L, Pallini R, Bagni C. FMRP modulates the Wnt signalling pathway in glioblastoma. *Cell Death Dis*. 2022 Aug 18;13(8):719.
28. Fratoni S, Trawinska MM, Capalbo A, Bernardini L, Fabbretti M, Martini M, Niscola P, Zhao XF. Correction to: Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement. *Virchows Arch*. 2022 Nov;481(5):815-816. doi: 10.1007/s00428-022-03395-4. Erratum for: *Virchows Arch*. 2022 Jul 26;: PMID: 35960371.
29. Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. *J Pers Med*. 2022 Jun 29;12(7):1073.

30. Fiorentino V, Tralongo P, Martini M, Betti S, Rossi E, Pierconti F, De Stefano V, Larocca LM. A Novel Morphological Parameter Predicting Fibrotic Evolution in Myeloproliferative Neoplasms: New Evidence and Molecular Insights. *Int J Mol Sci.* 2022 Jul 17;23(14):7872.
31. Fratoni S, Trawinska MM, Capalbo A, Bernardini L, Fabbretti M, Martini M, Niscola P, Zhao XF. Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement. *Virchows Arch.* 2022 Dec;481(6):975-979. doi: 10.1007/s00428-022-03386-5. Epub 2022 Jul 26.
32. Ragonese M, Gianfrancesco LD, Palermo G, Pierconti F, Martini M, Foti M, Bassi P, Racioppi M. The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer. *Clin Genitourin Cancer.* 2022 Aug;20(4):e271-e275.
33. Pizzimenti C, Fiorentino V, Ieni A, Martini M, Tuccari G, Lentini M, Fadda G. Aggressive variants of follicular cell-derived thyroid carcinoma: an overview. *Endocrine.* 2022 Oct;78(1):1-12.
34. Dell'Aquila M, Tralongo P, Granitto A, Martini M, Capodimonti S, Curatolo M, Fiorentino V, Pontecorvi A, Fadda G, Lombardi CP, Raffaelli M, Pantanowitz L, Larocca LM, Rossi ED. Update regarding the role of PD-L1 in oncocytic thyroid lesions on cytological samples. *J Clin Pathol.* 2023 Oct;76(10):671-677.
35. Lauretti L, Cenci T, Montano N, Offi M, Giordano M, Caccavella VM, Mangraviti A, Agostini L, Olivi A, Gabriele L, Larocca LM, Pallini R, Martini M, D'Alessandris QG. Molecular Analysis in a Glioblastoma Cohort-Results of a Prospective Analysis. *J Pers Med.* 2022 Apr 26;12(5):685.
36. Nocini R, Vianini M, Girolami I, Calabrese L, Scarpa A, Martini M, Morbini P, Marletta S, Brunelli M, Molteni G, Parwani A, Pantanowitz L, Eccher A. PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to the bedside. *Clin Exp Dent Res.* 2022 Jun;8(3):690-698.
37. Gandi C, Totaro A, Bientinesi R, Marino F, Pierconti F, Martini M, Russo A, Racioppi M, Bassi P, Sacco E. A multi-surgeon learning curve analysis of overall and site-specific positive surgical margins after RARP and implications for training. *J Robot Surg.* 2022 Dec;16(6):1451-1461.
38. Guerini Rocco E, Eccher A, Girolami I, Graziano P, Fontanini G, Vigliar E, Troncone G, Barberis M, Morbini P, Martini M. Concordance between Three PD-L1 Immunohistochemical Assays in Head and Neck Squamous Cell Carcinoma (HNSCC) in a Multicenter Study. *Diagnostics (Basel).* 2022 Feb 13;12(2):477.
39. Cuccaro A, Bellesi S, Galli E, Zangrilli I, Corrente F, Cupelli E, Fatone F, Maiolo E, Alma E, Viscovo M, D'Alò F, Annunziata S, Martini M, Rufini V, Giordano A, De Stefano V, Larocca LM, Hohaus S. PD-L1 expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma. *J Leukoc Biol.* 2022 Sep;112(3):539-545.
40. Pierconti F, Martini M, Cenci T, Fiorentino V, Gianfrancesco LD, Ragonese M, Bientinesi R, Rossi E, Larocca LM, Racioppi M, Bassi PF. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma. *Urol Oncol.* 2022 Mar;40(3):108.e19-108.e25.
41. D'Alessandris QG, Martini M, Cenci T, Di Bonaventura R, Lauretti L, Stumpo V, Olivi A, Larocca LM, Pallini R, Montano N. Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach. *J Neurosurg Sci.* 2023 Feb;67(1):103-107.
42. Cuccaro A, Bellesi S, Galli E, Zangrilli I, Corrente F, Cupelli E, Fatone F, Maiolo E, Alma E, Viscovo M, D'Alò F, Annunziata S, Martini M, Rufini V, Giordano A, De Stefano V, Larocca LM, Hohaus S. PD-L1

expression in peripheral blood granulocytes at diagnosis as prognostic factor in classical Hodgkin lymphoma. *J Leukoc Biol.* 2022 Jan 20.

43. Barresi V, Simbolo M, Mafficini A, Martini M, Calicchia M, Piredda ML, Ciaparrone C, Bonizzato G, Ammendola S, Caffo M, Pinna G, Sala F, Lawlor RT, Ghimenton C, Scarpa A. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. *Acta Neuropathol Commun.* 2021 Dec 24;9(1):200.
44. Santoro A, Travaglino A, Inzani F, Arciuolo D, Angelico G, D'Alessandris N, Scaglione G, Valente M, Martini M, Raffone A, Zannoni GF. Clear cell endometrial carcinoma precursors: presentation of two cases and diagnostic issues. *Diagn Pathol.* 2021 Oct 25;16(1):95.
45. Calegari MA, Stefano BD, Basso M, Carbone C, Camarda F, Ribelli M, Anghelone A, Vivolo R, Bensi M, Martini M, Pozzo C, Vellone M, Ardito F, Salvatore L, Giuliani F, Tortora G. Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report. *Clin Colorectal Cancer.* 2021 Dec;20(4):364-367.
46. Pierconti F, Martini M, Fiorentino V, Cenci T, Racioppi M, Foschi N, Di Gianfrancesco L, Sacco E, Rossi E, Larocca LM, Bassi PF. Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. *Hum Pathol.* 2021 Dec;118:42-48.
47. Cerbelli B, Girolami I, Eccher A, Costarelli L, Taccogna S, Scialpi R, Benevolo M, Lucante T, Luigi Alò P, Stella F, Gemma Pignataro M, Fadda G, Perrone G, D'Amati G, Martini M. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study. *Histopathology.* 2022 Jan;80(2):397-406.
48. Carbone C, Piro G, Agostini A, Delfino P, De Sanctis F, Nasca V, Spallotta F, Sette C, Martini M, Ugel S, Corbo V, Cappello P, Bria E, Scarpa A, Tortora G. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. *J Immunother Cancer.* 2021 Sep;9(9):e002876.
49. Buccarelli M, D'Alessandris QG, Matarrese P, Mollinari C, Signore M, Cappannini A, Martini M, D'Aliberti P, De Luca G, Pedini F, Boe A, Biffoni M, Pallini R, Ricci-Vitiani L. Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. *J Exp Clin Cancer Res.* 2021 Jul 12;40(1):228.
50. Giorgio A, Santullo F, Attalla El Halabieh M, Lodoli C, Abatini C, Calegari MA, Martini M, Rotolo S, Pacelli F. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer. *J Gastrointest Surg.* 2021 Oct;25(10):2649-2659.
51. Fiorentino V, Dell' Aquila M, Musarra T, Martini M, Capodimonti S, Fadda G, Curatolo M, Traini E, Raffaelli M, Lombardi CP, Pontecorvi A, Larocca LM, Pantanowitz L, Rossi ED. The Role of Cytology in the Diagnosis of Subcentimeter Thyroid Lesions. *Diagnostics (Basel).* 2021 Jun 6;11(6):1043.
52. Dell'Aquila M, Fiorentino V, Martini M, Capodimonti S, Cenci T, Lombardi CP, Raffaelli M, Pontecorvi A, Fadda G, Pantanowitz L, Larocca LM, Rossi ED. How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis. *Cancer Cytopathol.* 2021 Oct;129(10):819-829.
53. Eccher A, Fontanini G, Fusco N, Girolami I, Graziano P, Rocco EG, Martini M, Morbini P, Pantanowitz L, Parwani A, Pisano AM, Troncone G, Vigliar E. Digital Slides as an Effective Tool for Programmed Death Ligand 1 Combined Positive Score Assessment and Training: Lessons Learned from the "Programmed

Death Ligand 1 Key Learning Program in Head-and-Neck Squamous Cell Carcinoma". *J Pathol Inform.* 2021 Jan 8;12:1.

54. Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. *Cancer Immunol Immunother.* 2022 Jan;71(1):45-55.
55. Ardito F, Razionale F, Salvatore L, Cenci T, Vellone M, Basso M, Panettieri E, Calegari MA, Tortora G, Martini M, Giuliante F. Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. *Cancers (Basel).* 2021 Apr 29;13(9):2148.
56. Ferrara MG, Stefani A, Simbolo M, Pilotto S, Martini M, Lococo F, Vita E, Chiappetta M, Cancellieri A, D'Argento E, Trisolini R, Rindi G, Scarpa A, Margaritora S, Milella M, Tortora G, Bria E. Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. *Front Oncol.* 2021 Apr 15;11:650293.
57. Calegari MA, Salvatore L, Di Stefano B, Basso M, Orlandi A, Boccaccino A, Lombardo F, Auriemma A, Zurlo IV, Bensi M, Camarda F, Ribelli M, Vivolo R, Cocomazzi A, Pozzo C, Milella M, Martini M, Bria E, Tortora G. Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Retrospective Institutional Analysis (REBUS Study). *Cancers (Basel).* 2021 Apr 27;13(9):2098.
58. D'Alessandris QG, Pacioni S, Stumpo V, Buccarelli M, Lauretti L, Giordano M, Di Bonaventura R, Martini M, Larocca LM, Giannetti S, Montano N, Falchetti ML, Ricci-Vitiani L, Pallini R. Dilation of Brain Veins and Perivascular Infiltration by Glioblastoma Cells in an *In Vivo* Assay of Early Tumor Angiogenesis. *Biomed Res Int.* 2021 Mar 8;2021:8891045.
59. Servidei T, Meco D, **Martini M**, Battaglia A, Granitto A, Buzzonetti A, Babini G, Massimi L, Tamburrini G, Scambia G, Ruggiero A, Riccardi R. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. *Int J Mol Sci.* 2021 Feb 13;22(4):1877. doi: 10.3390/ijms22041877. PMID: 33668642; PMCID: PMC7918371.
60. Straccia P, **Martini M**, Pierconti F. Pericardial metastasis from alveolar rhabdomyosarcoma: A case report. *Diagn Cytopathol.* 2021 Feb 9. Doi 10.1002/dc.24717. Epub ahead of print. PMID: 33560576.
61. Ferrara MG*, **Martini M***, D'Argento E, Forcella C, Vita E, Di Noia V, Sperduti I, Bilotta M, Ribelli M, Damiano P, Cinnamon A, Stefani A, Pilotto S, Carbone C, Piro G, Milella M, Tortora G, Bria E. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. *Clin Lung Cancer.* 2021 Feb 5:S1525-7304(20)30351-X. doi: 10.1016/j.clcc.2020.12.008. Epub ahead of print. PMID: 33558194.
62. Schino M, Fiorentino V, Rossi E, Betti S, Di Cecca M, Ranucci V, Chiusolo P, **Martini M***, De Stefano V*, Larocca LM. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. *Haematologica.* 2020 Nov 19. doi: 10.3324/haematol.2020.264143. Epub ahead of print. PMID: 33543865.
63. Tassinari V, Cesarini V, Tomaselli S, Ianniello Z, Silvestris DA, Ginistrelli LC, **Martini M**, De Angelis B, De Luca G, Vitiani LR, Fatica A, Locatelli F, Gallo A. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. *Genome Biol.* 2021 Jan 28;22(1):51. doi: 10.1186/s13059-021-02271-9. PMID: 33509238; PMCID: PMC7842030.

64. Melotti L, Meco D, Battaglia A, Buzzonetti A, **Martini M**, Ruggiero A, Scambia G, Riccardi R. Targeting the mitogen-activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low-grade glioma cells. *Oncol Rep*. 2020 Nov 25. doi: 10.3892/or.2020.7867. Epub ahead of print. PMID: 33416182.
65. Fiorentino V*, **Martini M***, Dell'Aquila M, Musarra T, Orticelli E, Larocca LM, Rossi E, Totaro A, Pinto F, Lenci N, Di Paola V, Manfredi R, Bassi PF, Pierconti F. Histopathological Ratios to Predict Gleason Score Agreement between Biopsy and Radical Prostatectomy. *Diagnostics (Basel)*. 2020 Dec 23;11(1):10. doi: 10.3390/diagnostics11010010. PMID: 33374618; PMCID: PMC7822416.
66. Presacco S, Agnes AL, Magalini S, Carbone A, **Martini M**, Agnes A. Bleeding "sarcomatosis" as a rare presentation of vascular graft-related angiosarcoma: case report and review of the literature. *BMC Surg*. 2020 Nov 20;20(1):291. doi: 10.1186/s12893-020-00966-7. PMID: 33218319; PMCID: PMC7678180.
67. Lenci N, Francesco P, Scarciglia E, Fiorentino V, Schino M, Palermo G, Racioppi M, Bassi P, **Martini M**. Metanephric adenoma with BRAF V600K mutation and a doubtful radiological imaging: pitfalls in the diagnostic process. *Med Mol Morphol*. 2020 Nov 11. doi: 10.1007/s00795-020-00269-z. Epub ahead of print. PMID: 33175195.
68. Miele L, Alberelli MA, **Martini M**, Liguori A, Marrone G, Cocomazzi A, Vecchio FM, Landolfi R, Gasbarrini A, Grieco A, De Candia E. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. *Transl Res*. 2020 Nov 7:S1931-5244(20)30255-3. doi: 10.1016/j.trsl.2020.11.003. Epub ahead of print. PMID: 33171266.
69. Pierconti F, **Martini M**, Fiorentino V, Cenci T, Capodimonti S, Straccia P, Sacco E, Pugliese D, Cindolo L, Larocca LM, Bassi PF. The combination cytology/epicheck test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence? *Urol Oncol*. 2021 Feb;39(2):131.e17-131.e21. doi: 10.1016/j.urolonc.2020.06.018. Epub 2020 Aug 7. PMID: 32773233.
70. Straccia P, Rossi ED, **Martini M**, Mulè A, Cianfrini F, Curatolo M, Cancellieri A, Brunelli C, Zannoni GF, Fadda G. Description of a new biosafe procedure for cytological specimens from patients with COVID-19 processed by liquid-based preparations. *Cancer Cytopathol*. 2020 Dec;128(12):905-909. doi: 10.1002/cncy.22341. Epub 2020 Aug 7. PMID: 32767745; PMCID: PMC7436212.
71. Antonelli R, Jiménez C, Riley M, Servidei T, Riccardi R, Soriano A, Roma J, Martínez-Saez E, **Martini M**, Ruggiero A, Moreno L, Sánchez de Toledo J, Gallego S, Bové J, Hooker JM, Segura MF. CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. *Cancers (Basel)*. 2020 Jul 16;12(7):1922. doi: 10.3390/cancers12071922. PMID: 32708733; PMCID: PMC7409080.
72. Marano M, Brunelli C, De Marco C, **Martini M**, Quattrocchi CC, Lauriola L, Di Lazzaro V. Neuroimages and Neuropathology of a Stroke-Like Cerebral Lymphomatoid Granulomatosis. *Can J Neurol Sci*. 2021 Jan;48(1):114-115. doi: 10.1017/cjn.2020.133. Epub 2020 Jul 6. PMID: 32624028.
73. Girolami I, Pantanowitz L, Munari E, **Martini M**, Nocini R, Bisi N, Molteni G, Marchioni D, Ghimenton C, Brunelli M, Eccher A. Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta- analysis. *Head Neck*. 2020 Oct;42(10):3018-3030. doi: 10.1002/hed.26339. Epub 2020 Jun 22. PMID: 32567746.
74. D'alessandris QG, **Martini M**, Cenci T, Di Bonaventura R, Lauretti L, Stumpo V, Olivi A, Larocca LM, Pallini R, Montano N. Tailored therapy for recurrent glioblastoma. Report of a personalized molecular

approach. *J Neurosurg Ski*. 2020 Jun 17. doi: 10.23736/S0390-5616.20.04943-7. Epub ahead of print. PMID: 32550606.

75. Pierconti F, **Martini M**, Cenci T, Fiorentino V, Sacco E, Bientinesi R, Pugliese D, Iacovelli R, Schinzari G, Larocca LM, Bassi PF. Methylation study of the Paris system for reporting urinary (TPS) categories. *J Clin Pathol*. 2021 Feb;74(2):102-105. doi: 10.1136/jclinpath-2020-206633. Epub 2020 Jun 11. PMID: 32527754.
76. Buccarelli M, Lulli V, Giuliani A, Signore M, **Martini M**, D'Alessandris QG, Giannetti S, Novelli A, Ilari R, Giurato G, Boe A, Castellani G, Spartano S, Marangi G, Biffoni M, Genuardi M, Pallini R, Marziali G, Ricci-Vitiani L. Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. *Neuro Oncol*. 2020 Dec 18;22(12):1771-1784. doi: 10.1093/neuonc/noaa127. PMID: 32459347; PMCID: PMC7746944.
77. Brai A, Riva V, Saladini F, Zamperini C, Trivisani CI, Garbelli A, Pennisi C, Giannini A, Boccuto A, Bugli F, **Martini M**, Sanguinetti M, Zazzi M, Dreassi E, Botta M, Maga G. DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins. *Eur J Med Chem*. 2020 Aug 15;200:112319. doi: 10.1016/j.ejmech.2020.112319. Epub 2020 May 7. PMID: 32446036.
78. Lulli V, Buccarelli M, Ilari R, Castellani G, De Dominicis C, Di Gamberardino A, D'Alessandris QG, Giannetti S, **Martini M**, Stumpo V, Boe A, De Luca G, Biffoni M, Marziali G, Pallini R, Ricci-Vitiani L. Mir-370-3ps Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1. *Int J Mol Sci*. 2020 May 20;21(10):3610. doi: 10.3390/ijms21103610. PMID: 32443824; PMCID: PMC7279259.
79. Lupo F, Piro G, Torroni L, Delfino P, Trovato R, Rusev B, Fiore A, Filippini D, De Sanctis F, Manfredi M, Marengo E, Lawlor RT, **Martini M**, Tortora G, Ugel S, Corbo V, Melisi D, Carbone C. Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo. *Front Cell Dev Biol*. 2020 Apr 28;8:308. doi: 10.3389/fcell.2020.00308. PMID: 32411709; PMCID: PMC7198708.
80. Fioravanzo A, Caffo M, Di Bonaventura R, Gardiman MP, Ghimenton C, Ius T, Maffei V, **Martini M**, Nicolato A, Pallini R, Pegolo E, Pinna G, Sala F, Skrap M, Volpin V, Barresi V. A Risk Score Based on 5 Clinico-Pathological Variables Predicts Recurrence of Atypical Meningiomas. *J Neuropathol Exp Neurol*. 2020 May 1;79(5):500-507. doi: 10.1093/jnen/nlaa018. PMID: 32232472.
81. Strippoli A, Cocomazzi A, Basso M, Cenci T, Ricci R, Pierconti F, Cassano A, Fiorentino V, Barone C, Bria E, Ricci-Vitiani L, Tortora G, Larocca LM, **Martini M**. c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. *Cancers (Basel)*. 2020 Mar 10;12(3):638. doi: 10.3390/cancers12030638. PMID: 32164324; PMCID: PMC7139615.
82. Pierconti F, Raspollini MR, **Martini M**, Larocca LM, Bassi PF, Bientinesi R, Baroni G, Minervini A, Petracco G, Pini GM, Patriarca C. Correction to: PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG- unresponsive patients and BCG responders. *Virchows Arch*. 2020 Aug;477(2):327. doi: 10.1007/s00428-020-02791-y. Erratum for: *Virchows Arch*. 2020 Aug;477(2):269-277. PMID: 32157466.
83. Dell'Aquila M, Granitto A, **Martini M**, Capodimonti S, Cocomazzi A, Musarra T, Fiorentino V, Pontecorvi A, Lombardi CP, Fadda G, Pantanowitz L, Larocca LM, Rossi ED. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker. *Cancer Cytopathol*. 2020 Mar;128(3):177-189. doi: 10.1002/cncy.22224. Epub 2019 Dec 10. PMID: 31821747.

84. Iacovelli R, Ciccarese C, Schinzari G, Rossi E, Maiorano BA, Astore S, D'Angelo T, Cinnamon A, Pirozzoli C, Teberino MA, Pierconti F, **Martini M**, Tortora G. Biomarkers of response to advanced prostate cancer therapy. *Expert Rev Mol Diagn*. 2020 Jan 27;1-11. doi: 10.1080/14737159.2020.1707669.
85. Maiolo E, Alma E, Napodano C, Gulli F, Bellesi S, Cuccaro A, Pocino K, D'Alo' F, Iachini M, **Martini M**, Larocca LM, De Stefano V, Basile U, Hohaus S. The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). *Leuk Lymphoma*. 2019 Dec 31;1-7. doi: 10.1080/10428194.2019.1706731.
86. Pacioni S, D'Alessandris QG, Buccarelli M, Boe A, **Martini M**, Larocca LM, Bolasco G, Ricci-Vitiani L, Falchetti ML, Pallini R. Brain Invasion along Perivascular Spaces by Glioma Cells: Relationship with Blood-Brain Barrier. *Cancers (Basel)*. 2019 Dec 19;12(1). pii: E18. doi: 10.3390/cancers12010018.
87. Straccia P, **Martini M**, Sacco E, Bassi PF, Pierconti F. Cytological features of micropapillary and plasmacytoid variants of urothelial carcinoma. *Diagn Cytopathol*. 2020 Feb;48(2):111-117. doi: 10.1002/dc.24331. Epub 2019 Oct 24.
88. Grande G, Milardi D, **Martini M**, Cenci T, Gulino G, Mancini F, Bianchi A, Pontecorvi A, Pierconti F. Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. *Front Endocrinol (Lausanne)*. 2019 Sep 11;10:619. doi: 10.3389/fendo.2019.00619. eCollection 2019.
89. Pierconti F, **Martini M**, Grande G, Larocca LM, Sacco E, Pugliese D, Gulino G, Bassi PF, Milardi D, Pontecorvi A. Germ Cell Neoplasia in situ (GCNIS) in Testis-Sparing Surgery (TSS) for Small Testicular Masses (STMs). *Front Endocrinol (Lausanne)*. 2019 Aug 7;10:512. doi: 10.3389/fendo.2019.00512. eCollection 2019.
90. Fiorentino V, Pierconti F, Lenci N, Calicchia M, Palermo G, Bassi P, Larocca LM, **Martini M**. Urinary bladder leiomyosarcoma with osteoclast-like multinucleated giant cells: a case report. *BMC Cancer*. 2019; 19(1):763.
91. Silvestris DA, Picardi E, Cesarini V, Fosso B, Mangraviti N, Massimi L, **Martini M**, Pesole G, Locatelli F, Gallo A. Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. *Genome Biol*. 2019 Feb 13;20(1):33.
92. Chiloiro S, Capoluongo ED, Schinzari G, Concolino P, Rossi E, **Martini M**, Cocomazzi A, Grande G, Milardi D, Maiorano BA, Giampietro A, Rindi G, Pontecorvi A, De Marinis L, Bianchi A. First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. *Front Endocrinol (Lausanne)*. 2019 Jun 12;10:365
93. Ricci R, **Martini M**, Ravegnini G, Cenci T, Milione M, Lanza P, Pierconti F, Santini D, Angelini S, Biondi A, Rosa F, Alfieri S, Clemente G, Persiani R, Cassano A, Pantaleo MA, Larocca LM. Preferential MGMT methylation could predispose a subset of KIT/PDGFR α -WT GISTs, including SDH-deficient ones, to respond to alkylating agents. *Clin Epigenetics*. 2019 Jan 7;11(1):2.
94. Porcu C, Sideri S, **Martini M**, Cocomazzi A, Galli A, Tarantino G, Balsano C. Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender. *Int J Mol Sci*. 2018 Dec 8;19(12).
95. Falchetti ML, D'Alessandris QG, Pacioni S, Buccarelli M, Morgante L, Giannetti S, Lulli V, **Martini M**, Larocca LM, Vakana E, Stancato L, Ricci-Vitiani L, Pallini R. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1. *Int J Cancer*. 2019 Mar 15;144(6):1331-1344.

96. D'Alessandris QG, Montano N, **Martini M**, Cenci T, Lauretti L, Stumpo V, Pignotti F, Olivi A, Fernandez E, Larocca LM, Pallini R. Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report. *Acta Neurochir (Wien)*. 2018 Dec;160(12):2387-2391.
97. Magnini D, Fuso L, Varone F, D'Argento E, **Martini M**, Pecoriello A, Di Noia V, Arciuolo D, Fadda G, Rindi G, Richeldi L. Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. *Mol Diagn Ther*. 2018 Dec;22(6):723-728.
98. Pierconti F, **Martini M**, Straccia P, Fiorentino V, Musarra T, Larocca LM, Lopez-Beltran A. Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. *APMIS*. 2018 Sep;126(9):705-709.
99. Buccarelli M, Marconi M, Pacioni S, De Pascalis I, D'Alessandris QG, **Martini M**, Ascione B, Malorni W, Larocca LM, Pallini R, Ricci-Vitiani L, Matarrese P. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. *Cell Death Dis*. 2018 Aug 6;9(8):841.
100. **Martini M**, de Pascalis I, D'Alessandris QG, Fiorentino V, Pierconti F, Marei HE, Ricci-Vitiani L, Pallini R, Larocca LM. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. *BMC Cancer*. 2018 May 10;18(1):553.
101. Rossi ED, **Martini M**, Capodimonti S, Cenci T, Bilotta M, Pierconti F, Pontecorvi A, Lombardi CP, Fadda G, Larocca LM. Morphology combined with ancillary techniques: An algorithm approach for thyroid nodules. *Cytopathology*. 2018 Oct;29(5):418-427.
102. Inno A, Di Noia V, **Martini M**, D'Argento E, Di Salvatore M, Arena V, Schinzari G, Orlandi A, Larocca LM, Cassano A, Barone C. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. *Pathol Oncol Res*. 2018 Mar 20.
103. Porcu C, Antonucci L, Barbaro B, Illi B, Nasi S, Martini M, Licata A, Miele L, Grieco A, Balsano C. Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. *Oncotarget*. 2018 Jan 20;9(10):9325-9343.
104. **Martini M**, Capodimonti S, Cenci T, Bilotta M, Fadda G, Larocca LM, Rossi ED. To Obtain More With Less: Cytologic Samples With Ancillary Molecular Techniques-The Useful Role of Liquid-Based Cytology. *Arch Pathol Lab Med*. 2018 Mar;142(3):299-307.
105. Spina V, Brusca A, Cuccaro A, **Martini M**, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. *Blood*. 2018 May 31;131(22):2413-2425.
106. De Pascalis I, Morgante L, Pacioni S, D'Alessandris QG, Giannetti S, **Martini M**, Ricci-Vitiani L, Malinverno M, Dejana E, Larocca LM, Roberto Pallini R. Endothelial trans-differentiation in glioblastoma recurring after radiotherapy. *Mod Pathol*. 2018 Sep;31(9):1361-1366.
107. Pierconti F, Rossi ED, **Martini M**, Sacco E, Bassi PF, Larocca LM. 34BetaE12 and Alfa-Methylacyl Coenzyme A Racemase (AMACR) Antibodies Better Than p63 Antibody Distinguish Normal and Neoplastic Glands in Prostatic Tissue With Thermal Artifacts. *Appl Immunohistochem Mol Morphol*. 2019 Apr;27(4):306-310.

108. Servidei T, Meco D, Muto V, Bruselles A, Cioffi A, Trivieri N, Lucchini M, Morosetti R, Mirabella M, **Martini M**, Caldarelli M, Lasorella A, Tartaglia M, Riccardi R. Novel SEC61G-EGFR fusion gene in pediatric ependymomas discovered by clonal expansion of stem cells in absence of exogenous mitogens. *Cancer Res* 2017 Nov 1;77(21):5860-5872.
109. Rossi ED, Mehrotra S, Kilic AI, Toslak IE, Lim-Dunham J, **Martini M**, Fadda G, Lombardi CP, Larocca LM, Barkan GA. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in the pediatric age group. *Cancer*. 2018 Jan;126(1):27-35.
110. De Stefano A, Rosanova M, Malapelle U, **Martini M**, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C. Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? *Int J Biol Markers*. 2017 Oct 31;32(4):e474-e477.
111. Rossi ED*, **Martini M***, Larocca LM*. When Somatic Mutations Are Associated With a Higher Aggressive Behavior-A Story of Announced Evidence. *JAMA Oncol*. 2017 Oct 1;3(10):1427-1428.
112. Rossi ED, **Martini M**, Cenci T, Capodimonti S, Larocca LM. The role of thyroid FNA cytology in pediatric malignant lesions: An overview of the literature. *Cancer*. 2017 Aug;125(8):594-603.
113. Rossi ED, **Martini M**. New Insight in a New Entity: NIFTPS and Valuable Role of Ancillary Techniques. The Role of PD-L1. *EBioMedicine*. 2017 Apr;18:11-12. IF. 1,923
114. Rossi S, Congedo T, Ricci R, **Martini M**, Di Noia V, Di Dio C, Quirino M, Barone C, Cassano A. Is surgery mandatory in locally advanced gastrointestinal stromal tumors after imatinib? A case report and literature review. *J Gastrointest Oncol*. 2017 Feb;8(1):E4-E9.
115. Marziali G, Buccarelli M, Giuliani A, Ilari R, Grande S, Palma A, D'Alessandris QG, **Martini M**, Biffoni M, Pallini R, Ricci-Vitiani L. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes. *Mol Oncol*. 2017 Sep;11(9):1115-1129.
116. Pierconti F, **Martini M**, Cenci T, Petrone GL, Ricci R, Sacco E, Bassi PF, Larocca LM. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System. *Prostate*. 2017 May;77(6):597-603. doi: 10.1002/pros.23299. Epub 2017 Feb 1. PubMed PMID: 28144985.
117. Willmann JK, Bonomo L, Testa A, Rinaldi P, Rindi G, Valluru KS, Petrone G, **Martini M**, Lutz AM, Gambhir SS. Ultrasound Molecular Imaging in Patients with Breast and Ovarian Lesions: First-In-Human Results. *Journal of Clinical Oncology*, 2017 Jul 1;35(19):2133-2140.
118. D'Alessandris QG,* Biffoni M,* **Martini M**,* Signore M, Stancato L, Ricci Vitiani L ,Larocca LM, Pallini R. The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. *Neuro-Oncology*, 2017 Aug 1;19(8):1097-1108. IF. 7,371 am
119. Cesarini V,* **Martini M**,* Ricci Vitiani L, Gravina GL, Di Agostino S, Graziani G, D'Alessandris QG, Pallini R, Larocca LM, Rossi P, Jannini ES, Dolci S. Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. *Oncotarget*, 2017 Feb 21;8(8):13223-13239. IF. 5,008
120. Rossi ED, Bizzarro T, **Martini M**, Larocca LM, Schmitt F, Vielh P. Cytopathology of Follicular Cell Nodules. *Adv Anat Pathol*. 2017 Jan;24(1):45-55.
121. Pierconti F, **Martini M**, Cenci T, Larocca LM. The Immunohistochemical Analysis of SOCS3 Protein Identifies a Subgroup of Prostatic Cancer Biopsies With Aggressive Behavior. *Appl Immunohistochem Mol Morphol*. 2016 Oct 31

122. Rossi ED,* **Martini M**,* Bizzarro T, Schmitt F, Longatto-Filho A, Larocca LM. Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. *Oncotarget*. 2017 Jan 10;8(2):3746-3760. IF. 5,008
123. Bizzarro T, **Martini M**, Capodimonti S, Straccia P, Lombardi CP, Pontecorvi A, Larocca LM, Rossi ED. Young investigator challenge: The morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cytology: Some insights into their identification. *Cancer*. 2016 Oct;124(10):699-710.
124. Rodriquenz MG, Rossi S, Ricci R, **Martini M**, Larocca M, Dipasquale A, Quirino M, Schinzari G, Basso M, D'Argento E, Strippoli A, Barone C, Cassano A. Gastrointestinal stromal tumors (GISTs) and second malignancies: A novel "sentinel tumor"? A monoinstitutional, STROBE-compliant observational analysis. *Medicine (Baltimore)*. 2016 Sep;95(38):e4718.
125. Quero G, Musarra T, Carrato A, Fici M, **Martini M**, Dei Tos AP, Alfieri S, Ricci R. Unusual focal keratin expression in plexiform angiomyxoid myofibroblastic tumor: A case report and review of the literature. *Medicine (Baltimore)*. 2016 Jul;95(28):e4207.
126. Rossi ED, Bizzarro T, Granja S, **Martini M**, Capodimonti S, Luca E, Fadda G, Lombardi CP, Pontecorvi A, Larocca LM, Baltazar F, Schmitt F. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation. *Endocrine*. 2017 May;56(2):379-387.
127. Ricci R, **Martini M**, Cenci T, Riccioni ME, Maria G, Cassano A, Larocca LM. Divergent gastrointestinal stromal tumors in syndromic settings. *Cancer Genet*. 2016 Jul-Aug;209(7-8):354-8.
128. Rossi ED, Bizzarro T, **Martini M**, Capodimonti S, Cenci T, Fadda G, Schmitt F, Larocca LM. Morphological features that can predict BRAFV600E -mutated carcinoma in paediatric thyroid cytology. *Cytopathology*. 2017 Feb;28(1):55-64.
129. Strippoli A, Rossi S, **Martini M**, Basso M, D'Argento E, Schinzari G, Barile R, Cassano A, Barone C. ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. *Oncotarget*. 2016 Jun 7;7(23):35159-68.
130. Flex A, Biscetti F, Iachininoto MG, Nuzzolo ER, Orlando N, Capodimonti S, Angelini F, Valentini CG, Bianchi M, Larocca LM, **Martini M**,* Teofili L.* Human cord blood endothelial progenitors promote post-ischemic angiogenesis in immunocompetent mouse model. *Thromb Res*. 2016 May;141:106-11. IF. 2.32 am
131. Rossi ED, Bizzarro T, **Martini M**, Straccia P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. The role of fine-needle aspiration in the thyroid nodules of elderly patients. *Oncotarget*. 2016 Mar 15;7(11):11850-9.
132. Marziali G, Signore M, Buccarelli M, Grande S, Palma A, Biffoni M, Rosi A, D'Alessandris QG, **Martini M**, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. *Stem Cell Rep*. 2016 Feb 9;6:21557.
133. Bravi L, Malinverno M, Pisati F, Rudini N, Cuttano R, Pallini R, **Martini M**, Larocca LM, Locatelli M, Levi V, Bertani GA, Dejana E, Lampugnani MG. Endothelial Cells Lining Sporadic Cerebral Cavernous Malformation Cavernomas Undergo Endothelial-to-Mesenchymal Transition. *Stroke*. 2016 Mar;47(3):886-90.

134. Rossi ED, Bizzarro T, **Martini M**, Capodimonti S, Sarti D, Cenci T, Bilotta M, Fadda G, Larocca LM. The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms. *Endocrine*. 2016 Dec;54(3):723-732.
135. Cuccaro A, Annunziata S, Cupelli E, **Martini M**, Calcagni ML, Rufini V, Giachelia M, Bartolomei F, Galli E, D'Alò F, Voso MT, Leone G, Giordano A, Larocca LM, Hohaus S. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma. *Cancer Med*. 2016 Mar;5(3):398-406.
136. Orlandi A, Calegari MA, **Martini M**, Cocomazzi A, Bagalà C, Indelicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. *Clin Transl Oncol*. 2016 Oct;18(10):988-95
137. Rossi S, D'Argento E, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, **Martini M**, Cassano A, Barone C. Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. *Mol Diagn Ther*. 2016 Feb;20(1):55-63.
138. **Martini M**, Capodimonti S, Iachininoto MG, Cocomazzi A, Nuzzolo ER, Voso MT, Teofili L, Larocca LM. An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome. *Blood Cancer J*. 2015 Nov 27;5:e370. IF. 4,411 am
139. Dadduzio V, Basso M, Rossi S, Cenci T, Capodimonti S, Strippoli A, Orlandi A, Cerchiaro E, Schinzari G, Cassano A, **Martini M**, Barone C. KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. *Mol Diagn Ther*. 2016 Feb;20(1):65-74.
140. Tisi MC, Cupelli E, Santangelo R, Maiolo E, Alma E, Giachelia M, **Martini M**, Bellesi S, D'Alò F, Voso MT, Pompili M, Leone G, Larocca LM, Hohaus S. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2016;57(3):628-34.
141. Rizzo D, Ruggiero A, **Martini M**, Rizzo V, Maurizi P, Riccardi R. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment. *Biomed Res Int*. 2015;2015:215135.
142. Lulli V, Buccarelli M, **Martini M**, Signore M, Biffoni M, Giannetti S, Morgante L, Marziali G, Ilari R, Pagliuca A, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. *Oncotarget*. 2015 Nov 10;6(35):37241-56.
143. Rossi ED,* **Martini M**,* Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights. *Cancer Cytopathol*. 2015 Oct;123(10):593-602. IF. 3,092
144. Bizzarro T, Martini M, Marrocco C, D'Amato D, Traini E, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM, Rossi ED. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology. *PLoS One*. 2015 Jul 17;10(7):e0132939.
145. Voso MT, Fabiani E, Zang Z, Fianchi L, Falconi G, Padella A, **Martini M**, Li Zhang S, Santangelo R, Larocca LM, Criscuolo M, La Brocca A, Cutcutache I, Rozen S, Simonetti G, Manfrini M, Martinelli G, Hohaus S, Leone G, Tan P, Tenen DG. Fanconi anemia gene variants in therapy-related myeloid neoplasms. *Blood Cancer J*. 2015 Jul 3;5:e323.
146. Teofili L,* **Martini M**,* Nuzzolo ER, Capodimonti S, Iachininoto MG, Cocomazzi A, Fabiani E, Voso MT, Larocca LM. Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible

- contribution of a defective vascular niche to myelodysplasia. *Neoplasia*. 2015 May;17(5):401-9. IF. 5,476
147. Ricci R, **Martini M**, Cenci T, Carbone A, Lanza P, Biondi A, Rindi G, Cassano A, Larghi A, Persiani R, Larocca LM. PDGFRA-mutant syndrome. *Mod Pathol*. 2015 Jul;28(7):954-64.
 148. Puglisi MA, Cenciarelli C, Tesori V, Cappellari M, **Martini M**, Di Francesco AM, Giorda E, Carsetti R, Ricci-Vitiani L, Gasbarrini A. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells. *J Pathol*. 2015 Aug;236(4):479-90.
 149. D'Alessandris QG, **Martini M**, Cenci T, Capo G, Ricci-Vitiani L, Larocca LM, Pallini R. VEGF isoforms as outcome biomarker for anti-angiogenic therapy in recurrent glioblastoma. *Neurology*. 2015 May 5;84(18):1906-8.
 150. Ricci R, Chiarello G, Attili F, Fuccio L, Alfieri S, Persiani R, Di Pietro S, **Martini M**, Costamagna G, Larocca LM, Larghi A. Endoscopic ultrasound-guided fine needle tissue acquisition biopsy samples do not allow a reliable proliferation assessment of gastrointestinal stromal tumours. *Dig Liver Dis*. 2015 Apr;47(4):291-5.
 151. Rossi ED, **Martini M**, Straccia P, Bizzarro T, Fadda G, Larocca LM. The potential of liquid-based cytology in lymph node cytological evaluation: the role of morphology and the aid of ancillary techniques. *Cytopathology*. 2016 Feb;27(1):50-8. doi: 10.1111/cyt.12229.
 152. Rossi ED, **Martini M**, Straccia P, Gerhard R, Evangelista A, Pontecorvi A, Fadda G, Maria Larocca L, Schmitt F. Is thyroid gland only a "land" for primary malignancies? role of morphology and immunocytochemistry. *Diagn Cytopathol*. 2015 May;43(5):374-80.
 153. Rossi ED, Bizzarro T, **Martini M**, Capodimonti S, Fadda G, Larocca LM, Schmitt F. Morphological parameters able to predict BRAFV600E -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. *Cancer Cytopathol*. 2014 Dec;122(12):883-91.
 154. Ricci R, **Martini M**, Cenci T, Antinori A, Cassano A, Larocca LM. Case of Rectal GI Stromal Tumor Demonstrating that KIT and PDGFRA Mutations Are Not Always Mutually Exclusive. *J Clin Oncol*. 2016 Apr 20;34(12):e107-9.
 155. Rossi ED, **Martini M**, Capodimonti S, Straccia P, Revelli L, Lombardi CP, Pontecorvi A, Santeusano G, Larocca LM, Fadda G. Well-differentiated Thyroid Cancer With a Minor Poorly Differentiated Component: Clonal Heterogeneity Through the Prognostic Role of CXCR4 and BRAF Analysis. *Appl Immunohistochem Mol Morphol*. 2015 Mar;23(3):196-201.
 156. Giona F, Teofili L, Capodimonti S, Laurino M, **Martini M**, Marzella D, Palumbo G, Diverio D, Foà R, Larocca LM. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. *Blood*. 2014 Jun 5;123(23):3677-9.
 157. Giachelia M, Bozzoli V, D'Alò F, Tisi MC, Massini G, Maiolo E, Guidi F, Cupelli E, **Martini M**, Larocca LM, Voso MT, Leone G, Hohaus S. Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker. *J Mol Diagn*. 2014 Jul;16(4):467-76.
 158. Natalicchio MI, Improta G, Zupa A, Cursio OE, Stampone E, Possidente L, Teresa Gerardi AM, Vita G, **Martini M**, Cassano A, Piccoli C, Romito S, Aieta M, Antonetti R, Barone C, Landriscina M. Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. *Future Oncol*. 2014 Apr;10(5):713-23.

159. Rossi ED, **Martini M**, Straccia P, Cocomazzi A, Pennacchia I, Revelli L, Rossi A, Lombardi CP, Larocca LM, Fadda G. Thyroglossal duct cyst cancer most likely arises from a thyroid gland remnant. *Virchows Arch*. 2014 Jul;465(1):67-72.
160. Pierconti F, Milardi D, **Martini M**, Grande G, Cenci T, Gulino G, Larocca LM, Rindi G, Pontecorvi A, De Marinis L. Pituitary-tumour-transforming-gene 1 expression in testicular cancer. *Andrology*. 2015 May;47(4):427-32.
161. Rossi ED*, **Martini M***, Capodimonti S, Cenci T, Straccia P, Angrisani B, Ricci C, Lanza P, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience. *Cancer Cytopathol*. 2014 Jul;122(7):527-35. IF. 3,092
162. Rossi ED, **Martini M**, Fadda G, Larocca LM. Papillary thyroid microcarcinoma: a painstaking category to manage. *Clin Endocrinol (Oxf)*. 2014 Nov;81(5):785-6.
163. Rossi ED, Straccia P, **Martini M**, Revelli L, Lombardi CP, Pontecorvi A, Fadda G. The role of thyroid fine-needle aspiration cytology in the pediatric population: an institutional experience. *Cancer Cytopathol*. 2014 May;122(5):359-67.
164. Di Bella S, Taglietti F, Cicalini S, Baiocchi A, **Martini M**, Galluccio G, Gouliouris T, Petrosillo N. Photoquizz. Holoinspiratory wheezing in a 46-year-old HIV-seropositive man. *Clin Infect Dis*. 2014 Jan;58(1):78, 134-5.
165. Rossi ED, **Martini M**, Straccia P, Raffaelli M, Pennacchia I, Marrucci E, Lombardi CP, Pontecorvi A, Fadda G. The cytologic category of oncocytic (Hurthle) cell neoplasm mostly includes low-risk lesions at histology: an institutional experience. *Eur J Endocrinol*. 2013 Oct 1;169(5):649-55.
166. Nuzzolo ER, Capodimonti S, **Martini M**, Iachininoto MG, Bianchi M, Cocomazzi A, Zini G, Leone G, Larocca LM, Teofili L. Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential. *Blood Transfus*. 2014 Jan;12 Suppl 1:s367-74.
167. Ricci-Vitiani L, Runci D, D'Alessandris QG, Cenci T, **Martini M**, Bianchi F, Maira G, Stancato L, De Maria R, Larocca LM, Pallini R. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin. *Neoplasia*. 2013 Jul;15(7):773-82.
168. **Martini M**, Santoro L, Familiari P, Costamagna G, Ricci R. Inflammatory fibroid polyp of the gallbladder bearing a platelet-derived growth factor receptor alpha mutation. *Arch Pathol Lab Med*. 2013 May;137(5):721-4. IF. 2,631
169. Lauriola L, Serini S, Granone P, Lanza P, **Martini M**, Calviello G, Ranelletti FO. Hu/elav RNA-binding protein HuR regulates parathyroid hormone related peptide expression in human lung adenocarcinoma cells. *Histol Histopathol*. 2013 Sep;28(9):1205-16.
170. Rossi ED, **Martini M**, Capodimonti S, Straccia P, Cenci T, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. *Eur J Endocrinol*. 2013 May 2;168(6):853-9.
171. Bussu F, Hohaus S, Bastanza G, Bozzoli V, Tisi MC, **Martini M**, Paludetti G, Almadori G. Clinical and prognostic features of lymphomas arising in the head and neck region: Our experience of preferential association of different histotypes with various sites of origin in ninety patients. *Clin Otolaryngol*. 2013 Jun;38(3):248-53.

172. Vecchiet J, Iachininoto MG, Capodimonti S, Nuzzolo ER, Falasca K, **Martini M**, Mancino P, Bianchi M, Leone AM, Ucciferri C, Larocca LM, Teofili L. Effect of antiviral therapy on pro-angiogenic hematopoietic and endothelial progenitor cells in HIV-infected people. *Thromb Res*. 2013 Mar;131(3):238-43.
173. Novello M, Coli A, Della Pepa GM, **Martini M**, Doglietto F, De Stefano V, Bellesi S, Pescarmona E, Lauriola L. (in print). Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor. *Neuropathology*. 2014 Apr;34(2):179-84.
174. Rossi ED, **Martini M**, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. *Cancer Cytopathol*. 2013 Jun;121(6):291-7.
175. Rossi ED, **Martini M**, Straccia P, Larocca LM, Fadda G. Detection of ectopic thyroid remnants: a serious diagnostic dilemma. When molecular biology and immunohistochemistry can solve the problem. *Pathol Res Pract*. 2013 Jan 15;209(1):59-61.
176. Basso M, Strippoli A, Orlandi A, **Martini M**, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C. KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. *Br J Cancer*. 2013 Jan 15;108(1):115-20.
177. Falasca K, Ucciferri C, Teofili L, Iachininoto M, Capodimonti S, Nuzzolo ER, Bianchi M, **Martini M**, Vignale F, Pizzigallo E, Vecchiet J. Proangiogenic hematopoietic cells in acute HIV infection. *AIDS Res Hum Retroviruses*. 2013 Feb;29(2):307-10.
178. Teofili L, Nuzzolo ER, Vecchiet J, Falasca K, Iachininoto MG, **Martini M**, Larocca LM. Endothelial progenitor cells in HIV-positive patients: what are we talking about? *J Acquir Immune Defic Syndr*. 2013 Jan 1;62(1):e22-3.
179. **Martini M**, Cenci T, D'Alessandris GQ, Cesarini V, Cocomazzi A, Ricci-Vitiani L, De Maria R, Pallini R, Larocca LM. Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. *Cancer*. 2013 Mar 1;119(5):1004-12. IF. 5,649
180. D'Alessandris QG, Montano N, Cenci T, **Martini M**, Lauretti L, Bianchi F, Larocca LM, Maira G, Fernandez E, Pallini R. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. *Acta Neurochir (Wien)*. 2013 Jan;155(1):33-40.
181. Rossi ED, Revelli L, **Martini M**, Taddei A, Pintus C, Panunzi C, Fadda G. Cribriform-Morular Variant of Papillary Thyroid Carcinoma in an 8-Year-Old Girl: A Case Report With Immunohistochemical and Molecular Testing. *Int J Surg Pathol*. 2012 Dec;20(6):629-32.
182. de Paoli L, Cerri M, Monti S, Rasi S, Spina V, Brusca A, Greco M, Ciardullo C, Famà R, Cresta S, Maffei R, Ladetto M, **Martini M**, Laurenti L, Forconi F, Marasca R, Larocca LM, Bertoni F, Gaidano G, Rossi D. MGA, A Suppressor of MYC, is Recurrently Inactivated in High Risk Chronic Lymphocytic Leukemia. *Leuk Lymphoma*. 2013 May;54(5):1087-90.
183. Serio G, Zampatti C, Ballabio A, Ricci R, **Martini M**, Zurleni F. Neurofibromatosis 1 presenting with multiple duodenal GISTs associated with a somatostatin-producing D cell neoplasm. *Endocr Pathol*. 2013 Jun;24(2):100-5.

184. Cianci R, Cammarota G, Frisullo G, Pagliari D, Ianiro G, **Martini M**, Frosali S, Plantone D, Damato V, Casciano F, Landolfi R, Paola Batocchi A, Pandolfi F. Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet. *Clin Transl Gastroenterol*. 2012 Dec 13;3:e28.
185. Strisciuglio C, Corleto VD, Brunetti-Pierri N, Piccolo P, Sangermano R, Rindi G, **Martini M**, D'Armiento FP, Staiano A, Miele E. Autosomal dominant Ménétrier-like disease. *J Pediatr Gastroenterol Nutr*. 2012 Dec;55(6):717-20.
186. Capello D, Gloghini A, Baldanzi G, **Martini M**, Deambrogi C, Lucioni M, Piranda D, Famà R, Graziani A, Spina M, Tirelli U, Paulli M, Larocca LM, Gaidano G, Carbone A, Sinigaglia F. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma. *Hematol Oncol*. 2013 Mar;31(1):22-8.
187. Cenci T, **Martini M**, Montano N, D'Alessandris QG, Falchetti ML, Annibaldi D, Savino M, Bianchi F, Pierconti F, Nasi S, Pallini R, Larocca LM. Prognostic relevance of c-Myc and BMI1 expression in patients with glioblastoma. *Am J Clin Pathol*. 2012 Sep;138(3):390-6.
188. Rossi ED, **Martini M**, Cingolani N, Ranaldi R, Fadda G. Images in endocrine pathology: spindle cell lesion of the thyroid gland. *Endocr Pathol*. 2012 Jun;23(2):132-4.
189. Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, Ciardullo C, Famà R, Cresta S, Brusca A, Laurenti L, **Martini M**, Musto P, Forconi F, Marasca R, Larocca LM, Foà R, Gaidano G. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. *Br J Haematol*. 2012 Aug;158(3):426-9.
190. Leuzzi G, Cesario A, Vita ML, Parisi AM, Petrone G, **Martini M**, Rindi G, Granone P. Difference in clonality as a tool for differential diagnosis of primary versus secondary lung neoplasms. *J Thorac Oncol*. 2012 May;7(5):934-6.
191. Capodimonti S, Teofili L, **Martini M**, Cenci T, Iachininoto MG, Nuzzolo ER, Bianchi M, Murdolo M, Leone G, and Larocca LM. von Hippel Lindau disease and erythrocytosis. *J Clin Oncol*. 2012 May 1;30(13):e137-9.
192. Giona F, Teofili L, Moleti ML, **Martini M**, Palumbo G, Amendola A, Mazzucconi MG, Testi AM, Pignoloni P, Orlando SM, Capodimonti S, Nanni M, Leone G, Larocca LM, Foà R. Thrombocytopenia and polycythemia in patients younger than 20 years at diagnosis: clinical and biological features, treatment, and long-term outcome. *Blood*. 2012 Mar 8;119(10):2219-27.
193. Montano N*, Cenci T*, **Martini M***, D'Alessandris QG, Pelacchi F, Ricci-Vitiani L, Maira G, De Maria R, Larocca LM, Pallini R. Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited. *Neoplasia*. 2011 Dec;13(12):1113-21. IF. 5,476
194. Giachelia M, Voso MT, Tisi MC, **Martini M**, Bozzoli V, Massini G, D'Alò F, Larocca LM, Leone G, Hohaus S. Interleukin-6 plasma levels are modulated by a polymorphism in the NF- κ B1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. *Leuk Lymphoma*. 2012 Mar;53(3):411-6.
195. Rossi D, Spina V, Forconi F, Capello D, Fangazio M, Rasi S, **Martini M**, Gattei V, Ramponi A, Larocca LM, Bertoni F, Gaidano G. Molecular history of richter syndrome: Origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. *Int J Cancer*. 2012 Jun 15;130(12):3006-10.

196. **Martini M**, Ferrara AM, Giachelia M, Panieri E, Siminovitch K, Galeotti T, Larocca LM, Pani G. Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. *Inflamm Bowel Dis*. 2012 Mar;18(3):439-48. IF. 4,358
197. Inno A, Di Salvatore M, Cenci T, **Martini M**, Orlandi A, Strippoli A, Ferrara AM, Bagalà C, Cassano A, Larocca LM, Barone C. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? *Clin Colorectal Cancer*. 2011 Dec;10(4):325-32.
198. Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A, **Martini M**, Cesarini V, Cenci T, D'Alo F, Voso MT, Fadda G, Leone G, Larocca LM. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. *Clin Cancer Res*. 2011 May 1;17(9):2885-92.
199. Capello D, Gloghini A, **Martini M**, Spina M, Tirelli U, Bertoni F, Rinaldi A, Morra E, Rimbaldi A, Sinigaglia F, Larocca LM, Carbone A. Mutations of CD79a, CD79b and EZH2 genes in immunodeficiency-related non-hodgkin lymphomas. *Br J Haematol*. 2011 Mar;152(6):777-80.
200. Teofili L*, **Martini M***, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, Cenci T, Larocca LM, Leone G. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. *Blood*. 2011 Mar 3;117(9):2700-7. IF. 11,841 am
201. Rossi ED, Larghi A, Verna EC, **Martini M**, Galasso D, Carnuccio A, Larocca LM, Costamagna G, Fadda G. Endoscopic ultrasound-guided fine-needle aspiration with liquid-based cytologic preparation in the diagnosis of primary pancreatic lymphoma. *Pancreas*. 2010 Nov;39(8):1299-302.
202. Teofili L, Iachininoto MG, Capodimonti S, Ucciferri C, Nuzzolo ER, **Martini M**, Torti L, Falasca K, Vecchiet J, Leone G, Larocca LM. Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. *AIDS*. 2010 Oct 23;24:2443-50.
203. Pallini R, Ricci-Vitiani L, Montano N, Mollinari C, Biffoni M, Cenci T, Pierconti F, **Martini M**, De Maria R, Larocca LM. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. *Cancer*. 2011 Jan 1;117(1):162-74.
204. Pierconti F*, **Martini M***, Pinto F, Cenci T, Capodimonti S, Calarco A, Bassi PF, Larocca LM. Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior. *Prostate*. 2011 Feb 15;71(3):318-25. IF. 3,778
205. Teofili L, Giona F, **Martini M**, Torti L, Cenci T, Foà R, Leone G, and Larocca LM. MPL activation, thrombopoietin mimetic drugs and hereditary thrombocytosis: remarks on bone marrow fibrosis. *J Clin Oncol*. 2010 Jul 1;28(19):e317-8.
206. Capello D, Scandurra M, Poretti G, Rancoita PMV, Mian M, Gloghini A, Deambrogi C, **Martini M**, Rossi D, Greiner TC, Chan WC, Ponzoni M, Montes Moreno S, Piris MA, Canzonieri V, Spina M, Tirelli U, Inghirami G, Rinaldi A, Zucca E, Dalla Favera R, Cavalli F, Larocca LM, Kwee I, Carbone A, Gaidano G, Bertoni F. Genome wide DNA-profiling of HIV-related B-cell lymphomas. *Br J Haematol*. 2010 Jan;148(2):245-55.
207. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, Nunes V, Foà R, Leone G, **Martini M**, Larocca LM. MPLSer505Asn induced hereditary thrombocytosis is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. *Haematological*. 2010 Jan;95(1):65-70.

208. Liu K, **Martini M**, Rocca B, Amos CI, Teofili L, Giona F, Ding J, Komatsu H, Larocca LM, Skoda RC. Haematological. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. *Haematologica*. 2009 Oct;94(10):1368-74.
209. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, Laurenti L, Maffei R, Forconi F, Bertoni F, Zucca E, Agostinelli C, Cabras A, Lucioni M, **Martini M**, Magni M, Deaglio S, Ladetto M, Nomdedeu JF, Besson C, Ramponi A, Canzonieri V, Paulli M, Marasca R, Larocca LM, Carbone A, Pileri SA, Gattei V, Gaidano G. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to richter syndrome. *Clin Cancer Res*. 2009 Jul 1;15(13):4415-22.
210. Hohaus S, Giachelia M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D'Alò F, **Martini M**, Larocca LM, Voso MT, Leone G. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. *Ann Oncol*. 2009 Aug;20(8):1408-13.
211. Lucantoni C, De Bonis P, Doglietto F, Esposito G, Larocca LM, Mangiola A, **Martini M**, Papacci F, Teofili L, Pompucci A. Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. *J Neurooncol*. 2009 Sep;94(2):235-42.
212. Hohaus S, Giachelia M, Massini G, Vannata B, Criscuolo M, **Martini M**, D'Alo' F, Voso MT, Larocca LM, Leone G. Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. *Leuk Res*. 2009 Oct;33(10):1352-6.
213. Teofili L, Cenci T, **Martini M**, Capodimonti S, Torti L, Giona F, Amendola A, Randi ML, Putti MC, Scapin M, Leone G, Larocca LM. The mutant JAK2V617F allele burden in children with essential thrombocythemia. *Br J Haematol*. 2009 May;145(3):430-2.
214. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, **Martini M**, Maira G, Larocca LM, De Maria R. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. *Clin Cancer Res*. 2008 Dec 15;14(24):8205-12.
215. Marotta D, Sgambato A, Cerciello S, Magarelli N, **Martini M**, Larocca LM, Maccauro G. Soft tissue non-Hodgkin lymphoma of shoulder in a HIV patient: a report of a case and review of the literature. *World J Surg Oncol*. 2008 Oct 21;6:111.
216. **Martini M**, Pallini R, Luongo G, Cenci T, Lucantoni C and Larocca LM. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. *Int J Cancer*. 2008 Dec 15;123(12):2955-60. IF. 5,531
217. Teofili L*, **Martini M***, Cenci T, Guidi F, Torti L, Giona F, Foà R, Leone G, Larocca LM. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. *Int J Cancer*. 2008 Oct 1;123(7):1586-92. IF. 5,531
218. Capello D, **Martini M**, Gloghini A, Cerri M, Rasi S, Deambrogi C, Rossi D, Spina M, Tirelli U, Larocca LM, Carbone A, Gaidano G. Molecular analysis of immunoglobulin variable genes in human immunodeficiency virus-related non-Hodgkin's lymphoma reveals implications for disease pathogenesis and histogenesis. *Haematologica*. 2008 Aug;93(8):1178-85.
219. **Martini M**, Teofili L, Cenci T, Giona F, Torti L, Rea M, Foà R, Leone G, Larocca LM. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. *Haematologica*. 2008 Jul;93(7):1068-71. IF. 6,671
220. **Martini M**, Hohaus S, Petrucci G, Cenci T, Pierconti F, Massini G, Teofili L, Leone G, Larocca LM. Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma. *Am J Clin Pathol*. 2008 Mar;129(3):472-7. IF. 2,278

221. Reddicono G, Chiusolo P, Fiorini A, Farina G, Laurenti L, **Martini M**, Marchetti S, Fadda G, Leone G, Sica S. Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. *Leukemia*. 2007 Dec;21(12):2552-4.
222. Teofili L, Giona F, **Martini M**, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Leone G, Foa R, Larocca LM. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. *Blood* 2007 Nov;19(11):1026-30.
223. Miele L, Pierconti F, Forgione A, Vero V, Cammarota G, Molinari F, Masselli G, Capristo E, **Martini M**, LM Larocca, Civello IM, Gasbarrini G, Grieco A. Cystic lymphangioma of the mesentery and hyposplenism in celiac disease. *Eur. J. Gastroenterol Hepatol*. 2007 Nov;19(11):1026-30.
224. Hohaus S, Giachelia M, Di Febo A, **Martini M**, Massini G, Vannata B, D'Alo' F, Guidi F, Greco M, Pierconti F, Larocca LM, Voso MT, Leone G. Polymorphism in cytokine genes as prognostic markers in Hodgkin lymphoma. *Ann Oncol*. 2007 Aug;18(8):1376-81.
225. Teofili L, **Martini M**, Cenci T, Petrucci G, Torti L, Storti S, Guidi F, Leone G, Larocca LM. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. *Blood*. 2007 Jul 1;110(1):354-9.
226. Hohaus S, Mansueto G, Massini G, D'Alo' F, Giachelia M, **Martini M**, Larocca LM, Voso MT, Leone G. Glutathione-S-Transferase (GST) genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. *Leuk Lymphoma*, March 2007; 48(3): 564 – 569. (
227. Teofili L, Giona F, **Martini M**, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foa R, Larocca LM. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. *J Clin Oncol*. 2007 Mar 20;25(9):1048-53.
228. Scardocci A, Guidi F, D'Alo' F, Gumiero D, Fabiani E, Diruscio A, **Martini M**, Larocca LM, Zollino M, Hohaus S, Leone G, Voso MT. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. *Br J Cancer*. 2006 Oct 23;95(8):1108-13.
229. Voso MT, Gumiero D, D'Alo' F, Guidi F, Mansueto G, Di Febo AL, Massini G, **Martini M**, Larocca LM, Hohaus S, Leone G. DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. *Haematological*. 2006 Sep;91(9):1252-6.
230. **Martini M**, Capello D, Serraino D, Navarra A, Pierconti F, Cenci T, Gaidano G, Larocca LM. Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. *J Infect*. 2007 Mar;54(3):298-306. IF. 4,832
231. Larocca LM, **Martini M**. Pathology of Epstein-Barr virus-related lymphomas in HIV. *Haematological*. 2005 Sep;1 (5): 19-20.
232. Teofili L, **Martini M**, Guidi F, Gumiero D, Leone G, Larocca LM. The PRV-1 Gene Expression in Essential Thrombocythemia. *Blood* 2004, Nov 1;104(9):2995-6.
233. Ricci R, Arena V, Castri F, **Martini M**, Maggiano N, Murazio M, Pacelli F, Potenza AE, Vecchio FM, Larocca LM. Role of p16/INK4a in Gastrointestinal Stromal Tumor Progression. *Am J Clin Pathol*. 2004 Jul;122(1):35-43.
234. Arena V, **Martini M**, Luongo M, Capelli A, Larocca LM. Mutations of the BIK gene in human peripheral B-cell lymphomas. *Genes Chromosomes Cancer*. 2003 Sep;38(1):91-6.

235. Teofili L, **Martini M**, Luongo M, Diverio D, Capelli G, Breccia M, Lo Coco F, Leone G, Larocca LM. Hypermethylation of CpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. *Leukemia*. 2003 May;17(5):919-24.
236. **Martini M**, Luongo M, Teofili L, Di Mario A, Leone G, Larocca LM. Dysregulated expression of Bcl-xL in CD34+ cells isolated from patients with refractory anemia with excess of blasts during megakaryocytic differentiation. *Haematologica*. 2002 Dec;87(12):1342-3. IF. 6,671
237. Cammarota G, Cianci R, Grillo RL, **Martini M**, Di Campi C, Pompili M, Pignataro G, Cuoco L, De Lorenzo A, Gasbarrini G, Pandolfi F, Larocca LM. Relationship between gastric localization of hepatitis C virus and mucosa-associated lymphoid tissue in Helicobacter pylori infection. *Scand J Gastroenterol*. 2002 Oct;37(10):1126-32.
238. **Martini M**, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S, Zannoni G, Vittori G, Larocca LM. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. *Int J Cancer*. 2002 Dec 1;102(4):398-406. IF. 5,531
239. Teofili L*, **Martini M***, Luongo M, Di Mario A, Leone G, De Stefano V, Larocca LM. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. *J Clin Oncol*. 2002 Oct 15;20(20):4249-54. IF. 20,982
240. **Martini M**, D'Alo F, Hohaus S, Leone G, Larocca LM. Absence of structural mutations of the BAK gene in B cell lymphomas. *Haematologica*. 2002 Jun;87(6):661-2. IF. 6,671
241. Corsi DC, Ciaparrone M, Zannoni G, Mancini M, Cassano A, Specchia M, Pozzo C, **Martini M**, Barone C. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer. *Eur J Cancer*. 2002 Mar;38(4):527-34.
242. Fassone L, Cingolani A, **Martini M**, Migliaretti G, Oreste PL, Capello D, Gloghini A, Vivenza D, Dolcetti R, Carbone A, Antinori A, Gaidano G, Larocca LM. Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma. *AIDS Res Hum Retroviruses*. 2002 Jan 1;18(1):19-26.
243. Teofili L, **Martini M**, Di Mario A, Rutella S, Urbano R, Luongo M, Leone G, Larocca LM. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. *Blood*. 2001 Jul 15;98(2):495-7.
244. Ricci R, Maggiano N, **Martini M**, Mule AM, Pierconti F, Capelli A, Larocca LM. Primary malignant melanoma of the gallbladder in dysplastic naevus syndrome. *Virchows Arch*. 2001 Feb;438(2):159-65.
245. Falchetti ML, Pallini R, D'Ambrosio E, Pierconti F, **Martini M**, Cimino-Reale G, Verna R, Maira G, Larocca LM. In situ detection of telomerase catalytic subunit mRNA in glioblastoma multiforme. *Int J Cancer*. 2000 Dec 15;88(6):895-901.
246. **Martini M**, D'Alo F, Pierconti F, Ricci R, Capelli A, Leone G, Larocca LM. Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma. *Haematology*. 2000 Oct;85(10):1019-23. IF. 6,671
247. Cingolani A, Gastaldi R, Fassone L, Pierconti F, Giancola ML, **Martini M**, De Luca A, Ammassari A, Mazzone C, Pescarmona E, Gaidano G, Larocca LM, Antinori A. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. *J Clin Oncol*. 2000 Oct 1;18(19):3325-30.

248. Teofili L, Morosetti R, **Martini M**, Urbano R, Putzulu R, Rutella S, Pierelli L, Leone G, Larocca LM. Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation. Exp Hematol. 2000 May;28(5):519-26.

MONOGRAPHS AND CHAPTERS ON BOOKS

Martini M, Teofili L, Larocca LM. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia. in Methods Mol Med. Myeloid Leukemia: methods and protocols. Eds Lland H., Hertzberg M., Marlton P. Humana Press 2006; pp. 265-73.

***Authors have contributed equally to the realization of the scientific work or have seniorship.**

I consent to the processing of personal data in accordance with the dictates of the privacy law.

Messina 20-05-2024

A handwritten signature in black ink, appearing to read 'M. Martini', with a stylized flourish at the end.

Maurizio Martini, MD,PhD